New drug targets Parkinson's protein in first human test

NCT ID NCT07216066

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called ALN-SNCA in 46 people with early Parkinson's disease. The drug is designed to lower levels of a harmful protein, alpha-synuclein, in the brain. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALN-SNCA
What this could lead to: If it works, this could point toward a treatment that slows or stops Parkinson's disease progression by reducing harmful protein buildup in the brain.
What could go wrong: This is a very early, small Phase 1 study focused on safety, not effectiveness. The drug may not lower the protein enough or could cause side effects, and many early-stage drugs fail to advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction mood disorder Muscle Rigidity Parasomnias Parkinson disease primary dysautonomia Tremor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSONS DISEASE

Contacts and locations

Locations

Center for Human Drug Research
RECRUITING

Leiden, South Holland, 2333 CL, Netherlands
Montreal Neurological Institute and Hospital
RECRUITING

Montreal, Quebec, H3A 2B4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.